Mitosis is not a key target of microtubule agents in patient tumors
Top Cited Papers
- 1 February 2011
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 8 (4), 244-250
- https://doi.org/10.1038/nrclinonc.2010.228
Abstract
Mitosis-specific agents have, to date, not been clinically successful. By contrast, microtubule-targeting agents (MTAs) have a long record of success, usually attributed to the induction of mitotic arrest. Indeed, it was this success that led to the search for mitosis-specific inhibitors. We believe the clinical disappointment of mitosis-specific inhibitors stands as evidence that MTAs have been successful not only by interfering with mitosis but, more importantly, by disrupting essential interphase cellular mechanisms. In this Perspective we will review literature that supports a paradigm shift in how we think about one of our most widely used classes of chemotherapeutics-MTAs. We believe that the steady presence and constant physiological role of microtubules are responsible for the overall success of MTAs. While mitosis-specific inhibitors are effective on only a small fraction of the tumor mass (dividing cells), MTAs target tubulin, a protein that has crucial roles in both mitotic and non-mitotic cells.Keywords
This publication has 67 references indexed in Scilit:
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerCancer Research, 2010
- Regulators of the cytoplasmic dynein motorNature Reviews Molecular Cell Biology, 2009
- Kinesin superfamily motor proteins and intracellular transportNature Reviews Molecular Cell Biology, 2009
- Functional Dynamics of Polo-Like Kinase 1 at the CentrosomeMolecular and Cellular Biology, 2009
- BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In VivoCurrent Biology, 2007
- Estimating The Cost Of New Drug Development: Is It Really $802 Million?Health Affairs, 2006
- Peripheral neuropathy: A persisting challenge in paclitaxel-based regimesEuropean Journal Of Cancer, 2006
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Subcellular localization of the BRCA1 gene product in mitotic cellsGenes, Chromosomes and Cancer, 2002
- Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora KinasesMolecular and Cellular Biology, 2002